After analysing results from the first five phase III studies into taspoglutide, Roche has revealed that the drug has a positive effect on reducing blood glucose and may improve treatment options for patients with type 2 diabetes.
Through a range of mechanisms, including improvement of insulin secretion, suppression of abnormal glucose production by the liver and slowing food absorption through the gut, taspoglutide plays a key role in blood glucose metabolism.
Hal Barron, Global Head of Product Development at Roche commented: “These phase III studies have shown that treatment with once weekly taspoglutide leads to significantly improved blood glucose control, consistent weight loss, a minimal risk of hypoglycaemia, and manageable safety profile. We believe taspoglutide has the potential to become an important therapy for diabetic patients.”
Roche’s phase III clinical trials programme, T-emerge, includes placebo-controlled and active-comparator controlled studies with current standards of care in patients treated with metformin or other therapies.
Results showed that taspoglutide was generally well tolerated in the studies. The most frequently reported adverse events included nausea and vomiting but this is an expected occurrence in all medications in this class.
To find out more, please click on the link below: